Ultra-discretionary treatments are extremely vulnerable to the economic cycle, right? Stick with me, read through the article and you will see why INMD is a good risk-adjusted opportunity even through a recession.įirst off, let me explain what are the criteria I look for when owning a stock through a recession: Roughly 66% of revenue is generated in the US and the remaining internationally. InMode's products are currently sold in 63 countries and serve a clientele of aesthetic and wellness practitioners such as plastic surgeons, dermatologists, OB/GYNs and ENTs (Ear, Nose & Throat) and Ophthalmologists. INMD now has 220 direct sales reps and 69 distributors worldwide. The company also sells consumables (13% of revenue) that practitioners use for each individual treatment and contribute to the visibility of the model. Within the aesthetic solutions market, INMD develops and provides energy-based, minimally invasive surgical medical treatment solutions that primarily address three end markets: face and body contouring, aesthetics, and women's health. It was founded in 2008 (by Moshe Mizrahy (current CEO) and Dr Michael Kreindel (current CTO), taken public in 2019 and is headquartered in Yokneam, Israel.

Its products target an array of procedures including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, and skin appearance and texture. InMode designs, develops, manufactures and markets minimally-invasive and non-invasive aesthetic medical products. Shares are undervalued and have >50% upside potential from today's price. This company offers best-in-class margins and returns, has a dominant market position, has a rich product pipeline, and generates abundant cash to fund operations and growth.

Demand for InMode's ( NASDAQ: INMD) products will prove to be more resilient than the market is currently pricing in - even if a recession strikes.

The intelligent investor audio book